Journal article
Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases
SSC Hung, S Khan, CY Lo, AW Hewitt, RCB Wong
Pharmacology and Therapeutics | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2017
Abstract
The revolution of induced pluripotent stem cell (iPSC) technology provides a platform for development of cell therapy, disease modeling and drug discovery. Recent technological advances now allow us to reprogram a patient's somatic cells into induced pluripotent stem cells (iPSCs). Together with methods to differentiate these iPSCs into disease-relevant cell types, we are now able to model disease in vitro using iPSCs. Importantly, this represents a robust in vitro platform using patient-specific cells, providing opportunity for personalized precision medicine. Here we provide a review of advances using iPSC for drug development, and discuss the potential and limitations of iPSCs for drug di..
View full abstractGrants
Awarded by Childhood Eye Cancer Trust
Funding Acknowledgements
This work was supported by funding from the National Health and Medical Research Council (RW, #1084256), Medical Advances without Animals association fellowship (RW), the Ophthalmic Research Institute of Australia (RW), Childhood Cancer Trust (SH, AH, RW), the University of Melbourne (Louisa Jean De Bretteville Bequest: RW; Therapeutic Technologies Research Initiative: RW, AH, SH) and operational infrastructure support for Centre of Eye Research Australia from the Victorian Government Some vector graphics used in Fig. 1 were designed by Freepik.